- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, January 8, 2021
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A piece by HealthPayerIntelligence referenced a study published in the June 2020 issue of The American Journal of Managed Care® (AJMC®). The study, “Value-Based Insurance Design in Louisiana: Blue Cross Blue Shield’s Zero Dollar Co-pay Program,” found that enrollment in a value-based insurance design program that eliminated pharmacy co-pays for 4 chronic disease drug classes was associated with a large decline in health care spending.
A study published in the September 2020 issue of AJMC® was referenced in an article by SHRM. The study, “Policies to Address Surprise Billing Can Affect Health Insurance Premiums,” showed that in addition to protecting patients from receiving unexpected bills, policies to address surprise billing could reduce health insurance premiums by 1% to 5%.
A newscast by Spectrum News 1 spotlighted an article published on AJMC.com, the website of AJMC®. The article, “FDA's Revised Blood Donation Guidance for Gay Men Still Courts Controversy,” covered an FDA announcement that relaxed restrictions on gay men being allowed to donate blood, in light of the coronavirus disease 2019 pandemic. Under the new guidance, a man seeking to donate blood would need to wait only 3 months, instead of 1 year, after having sex with another man.
Mitigating Barriers to Cell and Gene Therapy Access
February 14th 2025Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, according to a white paper from the National Pharmaceutical Council.
Read More
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”
February 7th 2025Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Read More
